March 2026

The term “patent cliff” suggests a sudden, vertical drop from the heights of monopoly pricing into a dark abyss of […]

Section 1: Why the Orange Book Is the Most Underused Sales Tool in Pharma Every pharmaceutical vendor, from API suppliers

The pharmaceutical industry is currently navigating a period of structural volatility that threatens to dismantle the traditional blockbuster revenue model.

The pharmaceutical business operates on a singular economic premise: the finite nature of exclusivity. Unlike other sectors where brand equity

A patent is far more than a legal document; it is the foundational asset upon which entire companies are built,

There is a moment familiar to every pharma commercial strategist: you’re in a brand review meeting and someone asks, “When

Predict launch dates with litigation data The pharmaceutical industry operates on economic principles that make standard financial valuation models inadequate.

The pharmaceutical industry has a billion-dollar blind spot. Every year, revenue projections contain time bombs in the form of misread

The United States pharmaceutical market operates on a system of regulatory signals that dictate the flow of billions of dollars